Recent News

• 11.06.2025 - Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
• 11.03.2025 - Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
• 10.09.2025 - Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
• 09.17.2025 - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
• 09.17.2025 - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
• 09.17.2025 - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
• 08.19.2025 - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
• 08.19.2025 - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Recent Filings

• 11.03.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 8-K Current report
• 10.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.24.2025 - 8-K Current report
• 10.09.2025 - EX-99.1 EX-99.1
• 10.09.2025 - 8-K Current report
• 10.03.2025 - 3 Initial statement of beneficial ownership of securities
• 09.26.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 09.22.2025 - 8-K Current report
• 09.09.2025 - 8-K Current report